Drugs / Saruparib
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04005690 | Aug 2019 → Jun 2027 expected | pancreatic ductal adenocarcinoma | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT06713369 | Apr 2025 → Oct 2026 expected | — | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT05938270 | Sep 2023 → Jun 2026 | prostate cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05573724 | Nov 2022 → Apr 2023 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04550104 | Mar 2021 → Mar 2026 overdue | non-small cell lung carcinoma | University of Leeds | Recruiting | No outcome recorded |
| Phase 1 | NCT02264678 | Oct 2014 → Mar 2025 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07446855 | Mar 2026 → Mar 2030 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07336446 | Jan → Nov 2026 expected | prostate cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07060365 | Sep → Dec 2025 | ovarian carcinoma | AstraZeneca | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05797168 | Jun 2023 → Aug 2028 expected | endometrial cancer, lung adenocarcinoma, ovarian cancer, squamous cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05367440 | Jun 2022 → Apr 2031 expected | metastatic prostate carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05123482 | Oct 2021 → Sep 2027 expected | biliary tract cancer, breast carcinoma, endometrial cancer, non-small cell squamous lung carcinoma +1 | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04644068 | Nov 2020 → May 2027 expected | biliary tract cancer, breast cancer, cervical cancer, colorectal cancer +8 | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07832630 | Nov 2026 → Nov 2029 expected | cancer | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06769126 | Nov 2025 → Dec 2028 expected | small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07711002 | Oct 2026 → Jun 2031 expected | metastatic prostate carcinoma | AstraZeneca | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06952803 | Aug 2025 → Mar 2033 expected | prostate cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06380751 | Aug 2024 → Dec 2029 expected | breast cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06120491 | Nov 2023 → Sep 2027 expected | metastatic prostate carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06899061 Comparator | Mar 2025 → Feb 2026 overdue | high grade malignant neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | Results AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗
Robust anti-tumour activity is evident in preclinical models across multiple B7-H4 positive tumour types, including ovarian and cholangiocarcinoma tumours, with combination therapy resulting in higher anti-tumour activity than monotherapy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Saruparib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07060365 ↗ |
| Known as | AZD5305 | “This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion” NCT06713369 ↗11“Saruparib (AZD5305) is a new-generation PARP inhibitor that selectively inhibits and traps PARP1.” PMID 41979035 ↗ Apr 2026 “Saruparib (AZD5305) is a potent and selective inhibitor of PARP1, with minimal effect on PARP2.” NCT06380751 ↗ “Saruparib (AZD5305) given orally once daily” NCT05938270 ↗ “Saruparib (AZD5305) 60mg PO daily” NCT07832630 ↗ “AZD8205 and AZD5305 (saruparib)” NCT05123482 ↗ |
| Action | Inhibit | “AZD5305 is a highly potent and selective inhibitor of PARP1 with 500-fold selectivity for PARP1 over PARP2.” PMID 35929986 ↗ Nov 2022 |
| Modality | Other / unclassified | “PARP inhibitor” NCT04644068 ↗ |
| Route | Oral | “An oral formulations of ceralasertib and AZD5305 will be used.” NCT02264678 ↗ |
| Target | PARP1 | “AZD5305 is a highly potent and selective inhibitor of PARP1 with 500-fold selectivity for PARP1 over PARP2.” PMID 35929986 ↗ Nov 2022 |